Clinical Trials Logo

Clinical Trial Summary

Background : Patients with hereditary spherocytosis (HS) are characterized by increased red blood cell (RBC) fragility and a loss of RBC deformability. While the clinical variability of the disease may be heterogenous from one patient to another, some studies reported the occurrence of vascular complications, notably in patients who have been splenectomized. Purpose : The aim of the study is to test the associations between the degree of vascular dysfunction and the extent of hemolysis, the amount of circulating microparticles, the level of erythrosis and the degree of RBC biophysical alterations. Abstract : Recent studies reported the occurrence of vascular complications in patients with HS, notably in patients who have previously been splenectomized. However, the exact reasons of these complications are unknown and no study investigated the vascular function in HS patients. Main objective Highlight the presence of altered vascular function in HS patients and test the relationships with the level of hemolysis and circulating microparticles. Secondary objectives To evaluate the associations between clinical severity and 1) the level of vascular dysfunction and 2) several biomarkers (hemolysis, hematological parameters, circulating microparticles, erythrosis, RBC biophysical properties).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04451785
Study type Interventional
Source Hospices Civils de Lyon
Contact
Status Completed
Phase N/A
Start date August 26, 2020
Completion date August 26, 2022

See also
  Status Clinical Trial Phase
Withdrawn NCT01276561 - Single Incision Versus Standard Laparoscopic Splenectomy N/A
Terminated NCT01141621 - The Dallas Hereditary Spherocytosis Cohort Study N/A